Douglas E Williams
CIK 1184847 · EVP & President, R&D · last filed 2026-06-12
Douglas E Williams is an EVP & President, R&D who has filed 78 SEC Form 4 insider transactions across 11 companies since 2007. The most recent filing, for CAMP, was dated Jun 12, 2026. Across all open-market trades the lifetime net is −$3.7M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $2.9M across reported positions. 18 SEC filings were submitted jointly with BIOGEN INC.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
Filer Profile
20 WILLIAM STREET SUITE 145
WELLESLEY HILLS, MA 02481
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| CAMP | Director | — | $3.92 | — | $0 | 2 | 2026-06-12 |
| Climb Bio, Inc. (ELYM) Delisted | Director | — | $5.11 | — | $0 | 4 | 2026-06-08 |
| SANA | EVP & President, R&D | — | $2.90 | — | $0 | 3 | 2024-03-08 |
| Codiak BioSciences, Inc. (CDAK) Delisted | President & CEO | 7,655 | $0.06 | $436 | -$30.7K | 8 | 2023-03-30 |
| OVID | Director | 5,000 | $2.32 | $11.6K | $32.4K | 7 | 2021-05-18 |
| IRWD | Director | 87,800 | $3.62 | $318.3K | $0 | 5 | 2019-04-03 |
| Regulus Therapeutics Inc. (RGLS) Delisted | Director | — | $8.16 | — | $0 | 4 | 2016-06-03 |
| BIIB | EVP Research & Development | 11,817 | $218.72 | $2.58M | -$3.73M | 16 | 2015-06-22 |
| Cascadian Therapeutics, Inc. (ONTY) Delisted | Director | 19,961 | — | — | $0 | 8 | 2013-06-14 |
| ZYMOGENETICS INC (ZGEN) Delisted | Chief Executive Officer | 0 | $12.01 | $0 | $47.0K | 12 | 2010-10-12 |
| ANADYS PHARMACEUTICALS INC (ANDS) Delisted | Director | 4,500 | — | — | $4.7K | 4 | 2008-05-30 |
Recent Filings
78 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-06-12 | CAMP | Grant (A) | — | $0 | EDGAR |
| 2026-06-08 | Climb Bio, Inc. (ELYM) Delisted | Grant (A) | — | $0 | EDGAR |
| 2025-06-05 | Climb Bio, Inc. (ELYM) Delisted | Grant (A) | — | $0 | EDGAR |
| 2025-04-01 | Climb Bio, Inc. (ELYM) Delisted | Grant (A) | — | $0 | EDGAR |
| 2025-03-19 | CAMP | Grant (A) | — | $0 | EDGAR |
| 2024-11-12 | Climb Bio, Inc. (ELYM) Delisted | Grant (A) | — | $0 | EDGAR |
| 2024-03-08 | SANA | Grant (A) | — | $0 | EDGAR |
| 2023-11-03 | SANA | Grant (A) | — | $0 | EDGAR |
| 2023-04-11 | SANA | Grant (A) | — | $0 | EDGAR |
| 2023-03-30 | Codiak BioSciences, Inc. (CDAK) Delisted | Sell (S) | −41,667 | -$7.5K | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.